9 Meters Biopharma Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of its medical analysis and clinical research.
The company stated in the following press release that they use animals for product testing.
“The presentation highlighted preclinical data investigating the use of larazotide, a tight junction regulator, to reduce lung fibrosis in an animal model of idiopathic pulmonary fibrosis (IPF).” Read the following article
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
Company Website: https://www.9meters.com